MARKET

CARA

CARA

Cara Therapeutic
NASDAQ
0.9998
+0.0498
+5.24%
After Hours: 0.8275 -0.1723 -17.23% 17:51 03/04 EST
OPEN
1.000
PREV CLOSE
0.9500
HIGH
1.150
LOW
0.9710
VOLUME
2.24M
TURNOVER
0
52 WEEK HIGH
10.39
52 WEEK LOW
0.5000
MARKET CAP
54.47M
P/E (TTM)
-0.4631
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's After-Market Session
Vicarious Surgical shares moved upwards by 24.9% to $0.45 during Monday's after-market session. The company's, Q4 earnings came out today. Ekso Bionics Holdings (NASDAQ:EKSO) stock increased by 21.42% in the same session.
Benzinga · 2h ago
Recap: Cara Therapeutics Q4 Earnings
Cara Therapeutics reported its Q4 earnings on March 4. The company missed its earnings estimate by $0.59. Cara Therapeutic is expected to announce its earnings Monday. The firm's revenue was down $257 thousand from the same period last year.
Benzinga · 3h ago
Cara Therapeutics Q4 2023 Adj EPS $(0.590) Misses $(0.410) Estimate, Sales $3.000M Miss $9.421M Estimate
Cara Therapeutics reported quarterly sales of $3.000 million. The company missed the analyst consensus estimate of $9.421 million by 68.16 percent. Cara also reported quarterly losses of $0.590 per share and missed sales by 43.9 percent.
Benzinga · 3h ago
Cara Therapeutics GAAP EPS of -$0.59 misses by $0.23, revenue of $3M misses by $6.13M
Q4 GAAP EPS of -$0.59 misses by $0.23, revenue of $3M misses by $6.13M. Cara Therapeutics is a clinical-stage company developing drugs to treat cancer. The company posted a Q4 revenue of -8.0% and a GAAP loss of $2.2 million.
Seeking Alpha · 3h ago
After-Hours Earnings Report for March 4, 2024 : GTLB, AVAV, NWPX, SFIX, AKYA, TDUP, EOSE, NKTR, DSP, CARA, EKSO, AVAL
NASDAQ · 5h ago
Cara: Q4 Earnings Snapshot
Cara Therapeutics Inc. Reported a loss of $32.3 million in its fourth quarter. The biotechnology company posted revenue of $3 million. The results did not meet Wall Street expectations. For the year, the company reported a Loss of $118.5 million.
Barchart · 9h ago
Options Volatility and Implied Earnings Moves Today, March 04, 2024
TipRanks · 12h ago
Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
TipRanks · 12h ago
More
About CARA
Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).

Webull offers Cara Therapeutics Inc stock information, including NASDAQ: CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.